{"The": [0, 50, 115], "discovery": [1], "of": [2, 18, 59, 94], "immune": [3, 27, 60], "checkpoint": [4, 28, 61], "proteins": [5, 29], "such": [6, 64, 96], "as": [7, 65, 97], "PD-1/PDL-1": [8], "and": [9, 43, 46, 70, 76, 78, 107, 123], "CTLA-4": [10, 79], "represents": [11], "a": [12], "significant": [13], "breakthrough": [14], "in": [15, 34, 109, 127], "the": [16, 92, 121], "field": [17], "cancer": [19, 128], "immunotherapy.": [20, 114], "Therefore,": [21], "humanized": [22], "monoclonal": [23], "antibodies,": [24], "targeting": [25], "these": [26, 89], "have": [30], "been": [31], "utilized": [32], "successfully": [33, 54], "patients": [35, 85], "with": [36], "metastatic": [37], "melanoma,": [38], "renal": [39], "cell": [40], "carcinoma,": [41], "head": [42], "neck": [44], "cancers": [45], "non-small": [47], "lung": [48], "cancer.": [49], "US": [51], "FDA": [52], "has": [53], "approved": [55], "three": [56], "different": [57], "categories": [58], "inhibitors": [62, 67, 73], "(ICIs)": [63], "PD-1": [66], "(Nivolumab,": [68], "Pembrolizumab,": [69], "Cemiplimab),": [71], "PDL-1": [72, 102], "(Atezolimumab,": [74], "Durvalumab": [75], "Avelumab),": [77], "inhibitor": [80], "(Ipilimumab).": [81], "Unfortunately,": [82], "not": [83], "all": [84], "respond": [86], "favourably": [87], "to": [88, 112, 119], "drugs,": [90], "highlighting": [91], "role": [93], "biomarkers": [95], "Tumour": [98], "mutation": [99], "burden": [100], "(TMB),": [101], "expression,": [103], "microbiome,": [104], "hypoxia,": [105], "interferon-\u03b3,": [106], "ECM": [108], "predicting": [110], "responses": [111], "ICIs-based": [113], "current": [116], "study": [117], "aims": [118], "review": [120], "literature": [122], "updates": [124], "on": [125], "ICIs": [126], "therapy.": [129]}